Putting the February complete response letter firmly in the rearview mirror, Disc Medicine Inc. is gearing up for a second go at the U.S. FDA, this time on the back of positive top-line data from the ...

The med-tech industry remains resilient despite pressure from tariffs, supply chain challenges and shifting investor priorities, according to a report from Ernst & Young (EY). Companies in the U.S.

G2Gbio Inc. said it signed a platform evaluation agreement with United Biotechnology Co. Ltd. (UBT) to apply its microsphere ...

Eyepoint Inc. is cutting its workforce by about 53% and prioritizing its late-stage program for Duravyu (vorolanib intravitreal insert, EYP-1901) in diabetic macular edema, following a disappointing ...

For nearly three decades, the U.S. NIH has had the Office of Research on Women’s Health, which coordinates and supports ...

The Indian government issued a new drug pricing order that would impose a 30% cap on supply chain margins for 137 cancer drugs, expanding a 2019 pilot program that covered 42 cancer drugs.

Buoyed by recent positive data for an autologous product, Nouscom AG has closed a €120 million (US$134.6 million) series D to ...

Darmstadt, Germany’s Merck KGaA agreed to acquire London’s Silence Therapeutics plc in an all-cash deal worth $1.3 billion in ...

A decade ago, Amanda Randles and her colleagues could use a supercomputer to simulate only a few heartbeats through a patient ...

Revolution Medicines Inc.’s KRAS inhibitor, Rasonque (daraxonrasib), received a thumbs-up from the EMA’s Committee for ...

Estuary Biotherapeutics Inc. emerged from stealth with a $93 million series A financing led by RA Capital Management to develop gene therapies to treat autosomal dominant polycystic kidney disease ...

Life sciences investors are raising billions of dollars in fresh capital, with a cluster of new funds and acquisition vehicles positioning specialist firms for more biotech company formation and ...